The prognostic and predictive impact of HER2 alterations (amplification or mutation) in metastatic colorectal cancer (mCRC) was evaluated through a pooled analysis of eight major randomized clinical trials, involving 1,604 patients with RAS/BRAF wild-type, microsatellite-stable tumors. The key findings are as follows: ### Prognostic Impact: 1.
The prognostic and predictive impact of HER2 alterations (amplification or mutation) in metastatic colorectal cancer (mCRC) was evaluated through a pooled analysis of eight major randomized clinical trials, involving 1,604 patients with RAS/BRAF wild-type, microsatellite-stable tumors. The key findings are as follows:
### Prognostic Impact:
1. **Prevalence of HER2 Alterations**: Approximately 5% of patients had HER2 amplification or overexpression, while about 2% harbored activating HER2 mutations.
2. **Worse Survival Outcomes**: Patients with HER2-positive tumors had significantly worse outcomes compared to HER2-negative patients:
3. **HER2 Positivity as a Negative Prognostic Factor**: These survival differences persisted even after adjusting for covariates, confirming that HER2 positivity is an independent negative prognostic factor in mCRC.
### Predictive Impact:
1. **Objective Response Rates (ORR)**: The ORR was similar between HER2-positive and HER2-negative groups, indicating that HER2 status does not influence the initial response to treatment.
2. **Efficacy of Biologic Therapies**:
3. **HER2-Mutant Tumors**: These tumors also demonstrated worse overall survival but did not show a differential response to biologic therapies.
### Conclusion:
HER2 amplification or mutation is associated with poorer prognosis in mCRC but does not alter the efficacy of standard targeted therapies, such as chemotherapy with bevacizumab or anti-EGFR agents. These findings highlight the need for HER2-directed treatment strategies to improve outcomes in this subset of patients.
Introduction: Circulating tumor DNA (ctDNA) has emerged as a promising noninvasive biomarker for monitoring treatment response and residual disease in solid tumors. However, its prognostic value during neoadjuvant chemotherapy (NAC) for localized pancreatic ductal adenocarcinoma...
Introduction: Aspirin is one of the few interventions proven to reduce colorectal and other Lynch syndrome–associated cancers. The earlier CaPP2 trial established 600 mg daily aspirin as an effective chemopreventive strategy, but concerns regarding long-term...
Introduction: The TOPAZ-1 trial established durvalumab combined with gemcitabine and cisplatin (GemCis) as the first immunotherapy-based first-line standard of care for advanced biliary tract cancer (BTC). However, long-term survival outcomes and durability of benefit beyond...
Introduction: Somatostatin receptor (SSTR) PET/CT has become indispensable for diagnosing, staging, and monitoring neuroendocrine tumors (NETs). However, until now, there has been no standardized method for assessing treatment response using SSTR PET imaging. This international...
Introduction: Staging laparoscopy (SL) is recommended for patients with locally advanced gastric cancer to detect occult peritoneal metastases before curative treatment. However, its real-world utilization across Europe remains uncertain. This large GASTRODATA study evaluated the...
Introduction: Neoadjuvant immune checkpoint inhibitors have transformed the management of mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) locally advanced colorectal cancer, achieving unprecedented pathological response rates. Experimental evidence suggests that cyclooxygenase-2 (COX-2) inhibition may enhance...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.